Syneos Health (NASDAQ:SYNH) will be posting its quarterly earnings results after the market closes on Monday, March 18th. Analysts expect Syneos Health to post earnings of $0.73 per share for the quarter.

SYNH stock opened at $46.92 on Friday. The company has a debt-to-equity ratio of 0.99, a current ratio of 0.97 and a quick ratio of 0.97. Syneos Health has a 12 month low of $34.40 and a 12 month high of $56.34. The company has a market capitalization of $4.29 billion, a PE ratio of 24.19, a PEG ratio of 1.19 and a beta of 1.41.

A number of equities analysts have recently commented on the stock. Zacks Investment Research upgraded shares of Syneos Health from a “hold” rating to a “buy” rating and set a $58.00 price objective for the company in a research report on Tuesday, December 4th. ValuEngine lowered shares of Syneos Health from a “buy” rating to a “hold” rating in a research report on Thursday, February 28th. Barclays cut their price objective on shares of Syneos Health from $51.00 to $45.00 and set an “equal weight” rating for the company in a research report on Thursday, January 3rd. Finally, Robert W. Baird set a $60.00 price objective on shares of Syneos Health and gave the company a “buy” rating in a research report on Tuesday, January 8th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Syneos Health has an average rating of “Buy” and an average price target of $53.44.

In related news, General Counsel Jonathan Olefson bought 750 shares of the stock in a transaction that occurred on Monday, December 17th. The shares were acquired at an average cost of $41.27 per share, with a total value of $30,952.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Jason M. Meggs bought 3,650 shares of the stock in a transaction that occurred on Monday, December 17th. The stock was bought at an average cost of $41.25 per share, for a total transaction of $150,562.50. The disclosure for this purchase can be found here. Company insiders own 0.57% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first published by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2019/03/16/syneos-health-synh-set-to-announce-quarterly-earnings-on-monday.html.

Syneos Health Company Profile

Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.

Recommended Story: How is the LIBOR rate calculated?

Earnings History for Syneos Health (NASDAQ:SYNH)

Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.